Cyclacel Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Bio Green Med Solution

14/05/2024 22:01

* Cyclacel Pharmaceuticals Inc  CYCC.OQ  reported a
quarterly
adjusted loss of $2.27​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of $-7.05.  The mean expectation of two analysts
for the quarter was for a loss of $4.74 per share. Wall Street
expected results to range from $-4.93 to $-4.56 per share.
    * Revenue was $29.00 thousand​; analysts expected zero. 
    * The company reported a quarterly loss of $2.95 million.
    * Cyclacel Pharmaceuticals Inc shares had risen by 20.4%
this
quarter and lost 4.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 19.8%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cyclacel
Pharmaceuticals Inc is $11.00 
This summary was machine generated from LSEG data May 14 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -4.74          -2.27          Beat
 Dec. 31 2023      -5.89          -6.23          Missed
 Sep. 30 2023      -5.45          -7.35          Missed
 Jun. 30 2023      -7.55          -6.60          Beat